Finder may earn compensation from partners, but editorial opinions are our own. Advertiser Disclosure

How to buy ImmunoPrecise Antibodies stock | $6.58

Learn how to easily invest in ImmunoPrecise Antibodies stock.

ImmunoPrecise Antibodies Ltd
+ $0.27 ( + 4.28%)

ImmunoPrecise Antibodies Ltd is a biotechnology business based in the US. ImmunoPrecise Antibodies shares (IPA) are listed on the NASDAQ and all prices are listed in US Dollars. ImmunoPrecise Antibodies employs 73 staff and has a trailing 12-month revenue of around 0.00.

How to buy shares in ImmunoPrecise Antibodies

  1. Compare share trading platforms.Use our comparison table to help you find a platform that fits you.
  2. Open your brokerage account. Complete an application with your details.
  3. Confirm your payment details. Fund your account.
  4. Research the stock. Find the stock by name or ticker symbol – IPA – and research it before deciding if it's a good investment for you.
  5. Purchase now or later. Buy your desired number of shares with a market order or use a limit order to delay your purchase until the stock reaches a desired price.
  6. Check in on your investment. Optimize your portfolio by tracking your stock.

ImmunoPrecise Antibodies stock price (NASDAQ: IPA)

Use our graph to track the performance of IPA stocks over time.

ImmunoPrecise Antibodies shares at a glance

Information last updated 2021-10-17.
Latest market close$6.58
52-week range$1.17 - $33.34
50-day moving average $6.61
200-day moving average $7.52
Wall St. target priceN/A
PE ratio N/A
Dividend yield N/A (0%)
Earnings per share (TTM) $-0.46

Buy ImmunoPrecise Antibodies shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.
Name Product Asset types Option trade fee Annual fee Signup bonus
Stocks, Options, ETFs, Cryptocurrency
Free stock (chosen randomly with a value anywhere between $2.50 and $200)
Sign up using the "go to site" link
Make unlimited commission-free trades in stocks, funds, and options with Robinhood Financial.
J.P. Morgan Self-Directed Investing
Stocks, Bonds, Options, Mutual funds, ETFs
$0 + $0.65/contract
Sofi Invest
Stocks, ETFs, Cryptocurrency
Get one free stock worth up to $1,000
Open an account
A free way to invest in stocks, ETFs and crypto.
Vanguard Personal Advisor
Stocks, Options, Mutual funds, ETFs
$20 per year
Financial advice powered by relationships, not commissions.
Stocks, Bonds, Options, Mutual funds, ETFs, Cryptocurrency
$0 + $0.50/contract
$0 per month
Deposit qualifying assets of $5,000+
A platform built for all kinds of traders and all styles of trading
$0 per year
Get a free stock valued up to $350
Open your Futu brokerage account via Moomoo
Trade stocks on the US, Hong Kong, Shanghai and Shenzhen markets.

Compare up to 4 providers

*Signup bonus information updated weekly.

The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.

Is it a good time to buy ImmunoPrecise Antibodies stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

ImmunoPrecise Antibodies price performance over time

Historical closes compared with the close of $6.58 from 2021-10-15

1 week (2021-10-08) 8.40%
1 month (2021-09-17) -6.27%
3 months (2021-07-16) 21.18%
6 months (2021-04-16) -34.85%
1 year (2020-10-16) 271.75%
2 years (2019-10-17) 1,683.68%
3 years (2018-10-17) 814.40%
5 years (2016-10-13) N/A

ImmunoPrecise Antibodies financials

Revenue TTM $18.7 million
Gross profit TTM $11.4 million
Return on assets TTM -11.88%
Return on equity TTM -26.6%
Profit margin -53.49%
Book value $2.88
Market capitalisation $127.4 million

TTM: trailing 12 months

Shorting ImmunoPrecise Antibodies shares

There are currently 448,182 ImmunoPrecise Antibodies shares held short by investors – that's known as ImmunoPrecise Antibodies's "short interest". This figure is 18.3% down from 548,823 last month.

There are a few different ways that this level of interest in shorting ImmunoPrecise Antibodies shares can be evaluated.

ImmunoPrecise Antibodies's "short interest ratio" (SIR)

ImmunoPrecise Antibodies's "short interest ratio" (SIR) is the quantity of ImmunoPrecise Antibodies shares currently shorted divided by the average quantity of ImmunoPrecise Antibodies shares traded daily (recently around 101169.751693). ImmunoPrecise Antibodies's SIR currently stands at 4.43. In other words for every 100,000 ImmunoPrecise Antibodies shares traded daily on the market, roughly 4430 shares are currently held short.

To gain some more context, you can compare ImmunoPrecise Antibodies's short interest ratio against those of similar companies.

However ImmunoPrecise Antibodies's short interest can also be evaluated against the total number of ImmunoPrecise Antibodies shares, or, against the total number of tradable ImmunoPrecise Antibodies shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case ImmunoPrecise Antibodies's short interest could be expressed as 0.02% of the outstanding shares (for every 100,000 ImmunoPrecise Antibodies shares in existence, roughly 20 shares are currently held short) or 0.0258% of the tradable shares (for every 100,000 tradable ImmunoPrecise Antibodies shares, roughly 26 shares are currently held short).

Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against ImmunoPrecise Antibodies.

Find out more about how you can short ImmunoPrecise Antibodies stock.

ImmunoPrecise Antibodies share dividends

We're not expecting ImmunoPrecise Antibodies to pay a dividend over the next 12 months.

You may also wish to consider:

Have ImmunoPrecise Antibodies's shares ever split?

ImmunoPrecise Antibodies's shares were split on a 1:5 basis on 22 November 2020. So if you had owned 5 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your ImmunoPrecise Antibodies shares – just the quantity. However, indirectly, the new 400% higher share price could have impacted the market appetite for ImmunoPrecise Antibodies shares which in turn could have impacted ImmunoPrecise Antibodies's share price.

ImmunoPrecise Antibodies share price volatility

Over the last 12 months, ImmunoPrecise Antibodies's shares have ranged in value from as little as $1.17 up to $33.34. A popular way to gauge a stock's volatility is its "beta".

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while ImmunoPrecise Antibodies's is -0.1641. This would suggest that ImmunoPrecise Antibodies's shares have been inversely-correlated to the average (for this exchange) – so when the broader market trended up or down, ImmunoPrecise Antibodies has bucked the trend.

To put ImmunoPrecise Antibodies's beta into context you can compare it against those of similar companies.

ImmunoPrecise Antibodies overview

ImmunoPrecise Antibodies Ltd. , together with its subsidiaries, engages in antibody production and related services in the United States, Canada, Europe, and internationally. The company offers a range of antibodies, enzymes, enzyme activity assays, arthritis animal products, proteins, deiminated proteins, organoid growth factors, and hybridoma products for research purposes. Its services include custom antigen modeling, design, and manufacturing; B cell sorting, screening, and sequencing; custom, immune, and naive phage display production and screening; transgenic animals and multi-species antibody discovery; bi-specific, tri-specific, VHH, and VNAR (shark) antibody manufacturing; DNA cloning, protein and antibody downstream processing; antibody characterization on label-free biosensors and antibody engineering; transient and stable cell line generation; antibody optimization and humanization; hybridoma production with multiplexed, high-throughput screening, and clone-picking; and cryopreservation. The company has a research collaboration agreement with Pierre Fabre S. A for antibody discovery. ImmunoPrecise Antibodies Ltd.

Frequently asked questions

What percentage of ImmunoPrecise Antibodies is owned by insiders or institutions?
Currently 6.858% of ImmunoPrecise Antibodies shares are held by insiders and 7.475% by institutions.
How many people work for ImmunoPrecise Antibodies?
Latest data suggests 73 work at ImmunoPrecise Antibodies.
When does the fiscal year end for ImmunoPrecise Antibodies?
ImmunoPrecise Antibodies's fiscal year ends in April.
Where is ImmunoPrecise Antibodies based?
ImmunoPrecise Antibodies's address is: 3204?4464 Markham Street, Victoria, BC, Canada, V8Z 7X8
What is ImmunoPrecise Antibodies's ISIN number?
ImmunoPrecise Antibodies's international securities identification number is: CA45257F2008

More guides on Finder

Ask an Expert

You are about to post a question on

  • Do not enter personal information (eg. surname, phone number, bank details) as your question will be made public
  • is a financial comparison and information service, not a bank or product provider
  • We cannot provide you with personal advice or recommendations
  • Your answer might already be waiting – check previous questions below to see if yours has already been asked provides guides and information on a range of products and services. Because our content is not financial advice, we suggest talking with a professional before you make any decision.

By submitting your comment or question, you agree to our Privacy and Cookies Policy and Terms of Use.

Questions and responses on are not provided, paid for or otherwise endorsed by any bank or brand. These banks and brands are not responsible for ensuring that comments are answered or accurate.
Go to site